Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1576
Bassett Furniture
BSET
$166M
| $5.53M | ﹤0.01% |
752,361
-57,982
| -7% | -$365K |
|
|
STKL
1577
DELISTED
SunOpta
STKL
| $5.52M | ﹤0.01% |
1,175,300
+881,884
| +301% | +$3.12M |
|
|
ASRT
1578
DELISTED
Assertio
ASRT
| $5.52M | ﹤0.01% |
107,295
+3,036
| +3% | +$157K |
|
|
VISN
1579
Vistance Networks Inc
VISN
$2.66B
| $5.51M | ﹤0.01% |
+661,083
| New | +$6.53M |
|
|
ECHO
1580
DELISTED
Echo Global Logistics, Inc.
ECHO
| $5.5M | ﹤0.01% |
254,400
-19,000
| -7% | -$357K |
|
1581
Pixelworks
PXLW
$44.4M
| $5.5M | ﹤0.01% |
141,854
-1,026
| -0.7% | -$44.4K |
|
|
LAND
1582
Gladstone Land Corp
LAND
$358M
| $5.49M | ﹤0.01% |
346,361
+30,856
| +10% | +$432K |
|
|
TRVN
1583
DELISTED
Trevena, Inc.
TRVN
| $5.49M | ﹤0.01% |
5,858
+1,821
| +45% | +$1.21M |
|
|
PZN
1584
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $5.49M | ﹤0.01% |
1,009,450
-29,450
| -3% | -$137K |
|
|
AHT
1585
Ashford Hospitality Trust
AHT
$20.8M
| $5.49M | ﹤0.01% |
7,592
+564
| +8% | +$437K |
|
1586
ASE Group
ASX
$103B
| $5.48M | ﹤0.01% |
1,207,400
-1,412,749
| -54% | -$6.03M |
|
|
TA
1587
DELISTED
TravelCenters of America LLC
TA
| $5.47M | ﹤0.01% |
355,199
-6,000
| -2% | -$76.3K |
|
1588
Titan International
TWI
$445M
| $5.46M | ﹤0.01% |
3,743,240
+232,200
| +7% | +$312K |
|
|
PVLA
1589
Palvella Therapeutics
PVLA
$2.25B
| $5.46M | ﹤0.01% |
22,036
-1,015
| -4% | -$237K |
|
1590
Axsome Therapeutics
AXSM
$11.2B
| $5.46M | ﹤0.01% |
66,400
+14,300
| +27% | +$1.1M |
|
1591
Nature's Sunshine
NATR
$266M
| $5.46M | ﹤0.01% |
606,097
+40,600
| +7% | +$353K |
|
|
VXRT
1592
DELISTED
Vaxart
VXRT
| $5.46M | ﹤0.01% |
616,328
-1,557,400
| -72% | -$4.47M |
|
|
CYBE
1593
DELISTED
Cyberoptics Corp
CYBE
| $5.45M | ﹤0.01% |
169,200
+72,706
| +75% | +$2.03M |
|
1594
TriNet
TNET
$3.16B
| $5.44M | ﹤0.01% |
+89,300
| New | +$4.46M |
|
1595
Acadia Pharmaceuticals
ACAD
$4.87B
| $5.44M | ﹤0.01% |
112,200
+51,400
| +85% | +$2.47M |
|
1596
Ribbon Communications
RBBN
$377M
| $5.43M | ﹤0.01% |
1,382,500
-168,300
| -11% | -$611K |
|
|
BELFB
1597
Bel Fuse Inc Class B
BELFB
$4.19B
| $5.41M | ﹤0.01% |
504,423
-36,000
| -7% | -$329K |
|
1598
Prudential
PUK
$34.7B
| $5.41M | ﹤0.01% |
183,621
-716,854
| -80% | -$19M |
|
|
PPD
1599
DELISTED
PPD, Inc. Common Stock
PPD
| $5.41M | ﹤0.01% |
+201,900
| New | +$5.04M |
|
1600
Itaú Unibanco
ITUB
$81.6B
| $5.41M | ﹤0.01% |
+1,584,153
| New | +$5.14M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.